Spectral

Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders

Retrieved on: 
Venerdì, Giugno 7, 2024
Sepsis, Spectral, TSX, Meeting, Annual general meeting, Septic shock, Holding company

TORONTO, June 07, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual Meeting of shareholders (the "Shareholders") held earlier today (the "Meeting").

Key Points: 
  • TORONTO, June 07, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual Meeting of shareholders (the "Shareholders") held earlier today (the "Meeting").
  • The Company confirms that all resolutions put forward in the Management Information Circular dated April 19, 2024 (the "Circular") to its Shareholders were approved.
  • Results of the matters voted on at the Meeting are set out below.
  • Spectral's seven director nominees were elected:

Spectral AI Reaches 50% Enrollment at Burn Centers for U.S. Pivotal Burn Study

Retrieved on: 
Giovedì, Giugno 6, 2024
Spectral, Data, Patient, Research, Principal, Clinical trial, Burn, MDAI, University of California, Davis, UC, FDA, Principal investigator, Artificial intelligence, Nursing

This pivotal study, which is targeting enrollment of 240 patients, including both adult and pediatric subjects at multiple burn centers and emergency departments across the U.S., is expected to be the final clinical trial before seeking FDA approval in 2025.

Key Points: 
  • This pivotal study, which is targeting enrollment of 240 patients, including both adult and pediatric subjects at multiple burn centers and emergency departments across the U.S., is expected to be the final clinical trial before seeking FDA approval in 2025.
  • The completion of the pivotal study will address two primary objectives.
  • The U.S. pivotal study is currently enrolling patients at several leading burn centers in the U.S., with esteemed Principal Investigators overseeing the research.
  • A list of the burn centers currently enrolled in the Company’s U.S. pivotal study is below.

Spectral AI Set to Join Russell Microcap® Index

Retrieved on: 
Mercoledì, Maggio 29, 2024
Spectral, Artificial intelligence, Growth, MDAI

DALLAS, May 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective following the closing of US equity markets on Friday, June 28, 2024 according to a preliminary list of additions posted Friday, May 24, 2024.

Key Points: 
  • DALLAS, May 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective following the closing of US equity markets on Friday, June 28, 2024 according to a preliminary list of additions posted Friday, May 24, 2024.
  • Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.
  • FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.
  • “Spectral AI’s inclusion in the Russell Microcap® Index represents the latest milestone in our evolution as a public company,” said Peter M. Carlson, Chief Executive Officer.

Enveda Biosciences Announces Microsoft Collaboration and Reveals Foundation Model to “Read and Translate” Chemistry

Retrieved on: 
Mercoledì, Maggio 29, 2024
Biotechnology, Health, Pharmaceutical, Technology, Artificial Intelligence, Microsoft, Spectral, Science, Mass spectrometry, Doctor of Philosophy, Conceptual model, Collection, Chemistry, Azure, EVP, Language, AI, Drug discovery, PRISM, Data science, Nature, Business development, Management

Enveda Biosciences (“Enveda”), a biotechnology company using AI to translate nature into new medicines, announced today a new collaboration with Microsoft and released details on their work creating their Foundation Model, called PRISM, trained on the world’s largest collection of experimental mass spectra.

Key Points: 
  • Enveda Biosciences (“Enveda”), a biotechnology company using AI to translate nature into new medicines, announced today a new collaboration with Microsoft and released details on their work creating their Foundation Model, called PRISM, trained on the world’s largest collection of experimental mass spectra.
  • The collaboration with Microsoft includes access to compute resources needed to power Enveda’s novel drug discovery platform.
  • Enveda will use Microsoft Azure to scale its generative AI models, including the newly revealed model, PRISM.
  • “By combining Microsoft Azure infrastructure with Enveda's data, expertise, and vision, an entirely new realm of chemistry can be explored to identify new medicines.”

Spectral AI to Participate in Benzinga’s “AI Unleashed: Exploring the Possibilities” Virtual Event

Retrieved on: 
Martedì, Maggio 28, 2024
Spectral, Artificial intelligence, MDAI

DALLAS, May 28, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Peter M. Carlson, Chief Executive Officer of Spectral AI, is scheduled to participate in a fireside chat at Benzinga’s “AI Unleashed: Exploring the Possibilities” virtual event, taking place on May 30, 2024.

Key Points: 
  • DALLAS, May 28, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Peter M. Carlson, Chief Executive Officer of Spectral AI, is scheduled to participate in a fireside chat at Benzinga’s “AI Unleashed: Exploring the Possibilities” virtual event, taking place on May 30, 2024.

Spectral AI Announces Purchases of Over 100,000 Shares by Insiders

Retrieved on: 
Venerdì, Maggio 17, 2024
Spectral, Patient, Burn, DFU, Research and development, Ulcer, MDAI, Burns, Government, Artificial intelligence, Pharmaceutical industry

DALLAS, May 17, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that several of the Company’s officers and directors acquired approximately 113,000 shares of Spectral AI common stock in open market transactions on May 10, 2024 and May 15, 2024.

Key Points: 
  • DALLAS, May 17, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that several of the Company’s officers and directors acquired approximately 113,000 shares of Spectral AI common stock in open market transactions on May 10, 2024 and May 15, 2024.
  • Initial applications involve patients with burns and diabetic foot ulcers (DFU).
  • In February, the Company received UKCA Authorization to commence sales of its DeepView™ AI®– Burn in the UK.
  • In total, the Company has been awarded over $250 million in non-dilutive financial support from the US Government.

Spectral AI Announces Voting Results from 2024 Annual Meeting of Stockholders and the Appointment of Erich Spangenberg to the Board of Directors

Retrieved on: 
Mercoledì, Maggio 15, 2024
Spectral, Cardiovascular disease, KPMG, Pfizer, Market access, Shareholder, Corporation, AGM, MDAI, KPMG LLP, Health, Senior, MD, Population health, LLP, Artificial intelligence, Providence St. Joseph Health

DALLAS, May 15, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2024 Annual Meeting of Stockholders held on May 14, 2024 (the “AGM”).

Key Points: 
  • DALLAS, May 15, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2024 Annual Meeting of Stockholders held on May 14, 2024 (the “AGM”).
  • At the AGM, stockholders overwhelmingly approved each of the four proposals set forth by the Company.
  • Ms. Snyder is Senior Director, Corporate Accounts at Shockwave Medical, a medical device company focused on the treatment of cardiovascular disease.
  • Following the AGM, the Board of Directors unanimously approved the expansion of the Board from six to seven members and appointed Erich Spangenberg to the Board of Directors.

Spectral AI Announces 2024 First Quarter Financial Results

Retrieved on: 
Martedì, Maggio 7, 2024
Sale, FDA, Administration, ELOC, ASPR, PBS, Burn, SWAT, Human services, FY, DFU, Trial of the century, Artificial intelligence, Development, Assessment, MDAI, RCSI, Spectral, Patient, Acquisition, Health, Marketing, Ulcer, Clinical trial, Avita Medical, Growth, Pharmaceutical industry

DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter ended March 31, 2024 (“Q1 2024”) and provided an update on its ongoing business activities.

Key Points: 
  • DeepView AI®-Burn Devices Deployed in UK; Expect Commercial Revenue in 2H 2024
    DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter ended March 31, 2024 (“Q1 2024”) and provided an update on its ongoing business activities.
  • “During the first quarter we continued to execute against our strategic priorities resulting in significant accomplishments across the enterprise,” said Peter M. Carlson, CEO of Spectral AI.
  • Completed enrollment in our DFU training study in the US with expected completion of our DFU validation study in 2H 2024.
  • Additionally, Spectral AI entered into a fixed price standby equity purchase agreement (“SEPA”) with a long-only investor that includes a $12.5 million prepaid advance (“Advances”).

Spectral AI to Participate at the Sidoti Micro-Cap Virtual Investor Conference

Retrieved on: 
Giovedì, Maggio 2, 2024
MDAI, Spectral, Conference, Artificial intelligence, Interest

DALLAS, May 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that management is scheduled to present and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Investor Conference, taking place on May 8-9, 2024.

Key Points: 
  • DALLAS, May 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that management is scheduled to present and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Investor Conference, taking place on May 8-9, 2024.
  • The Company’s presentation will begin at 12:15 pm ET on May 9, 2024 and can be accessed live here .
  • Interested parties may also access the live and archived webcast of the presentation by visiting the Investors section of Spectral AI’s website at https://investors.spectral-ai.com/news-events/events .
  • Registration is free and participants do not need to be a client of Sidoti & Company LLC.

Spectral AI Names Erich Spangenberg CEO of its IP Focused Subsidiary and Explores Potential Spin-Off of that Subsidiary

Retrieved on: 
Mercoledì, Aprile 24, 2024
IP, Investment, Publication, SIM, Partnership, Artificial intelligence, MDAI, Spectral, Acquisition, Committee, Partner

DALLAS, April 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Erich Spangenberg has been appointed as the Chief Executive Officer of its health care IP-focused subsidiary, Spectral IP.

Key Points: 
  • DALLAS, April 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Erich Spangenberg has been appointed as the Chief Executive Officer of its health care IP-focused subsidiary, Spectral IP.
  • “Spectral AI is fortunate that our largest shareholder, Erich Spangenberg, has agreed to assume the CEO role at Spectral IP.
  • Erich has consistently been recognized for his unrivaled track record in global IP investment, monetization, enforcement, acquisition, and licensing,” said Pete Carlson, CEO of Spectral AI.
  • As CEO of Spectral IP, Erich will report to me and to our Board as he prepares Spectral IP for a potential spin-off.”
    Erich Spangenberg stated, “I believe Spectral IP represents a significant opportunity to deliver additional value to Spectral AI shareholders.